Reports
Sale
Global Genitourinary Drugs Market Share, Size, Analysis, Growth: By Indications: Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Others; By Drug Type; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Genitourinary Drugs Market Outlook
The global genitourinary drugs market reached a value of USD 48.46 billion in 2023, driven by the increasing prevalence of urinary tract infections across the globe. The market size is anticipated to grow at a CAGR of 3.1% during the forecast period of 2024-2032 to achieve a value of USD 63.78 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Market
The genitourinary system comprises of the kidneys, ureter, bladder, urethra, and genital organs which are crucial for reproduction and eliminating waste from the body. The system’s functionality can be impaired by congenital anomalies, infections, iatrogenic injuries, hydronephrosis, cancer, trauma, and inflammation. Globally, there is a surge in demand for genitourinary medications as a result of the increasing number of people who have these conditions. Genitourinary medications are prescribed to treat disorders of the urinary tract, reproductive organs, and excretory system.
- The genitourinary drugs market worldwide is anticipated to grow throughout the forecast period. One of the main factors propelling the market for genitourinary drugs is the increasing prevalence of genitourinary conditions like erectile dysfunction, ovarian cancer, sexually transmitted diseases, bladder cancer, and benign prostatic hyperplasia.
- The leading companies in the market are concentrating on developing medication formulations that assist in treating patients with persistent prostate cancer who have grown resistant to standard chemotherapeutic and hormone treatment agents.
- A number of multinational corporations are working with top biopharmaceutical companies to introduce next-generation treatments and boost their market share. This is helping in the genitourinary drugs market expansion, facilitating a notable increase in the number of pipeline medications that are currently undergoing late-stage clinical studies.
- Further, it is expected that the demand for genitourinary medications would increase in the approaching years due to rising financing for research and development initiatives and advancements in the healthcare infrastructure supported by governmental and non- governmental bodies of many countries.
Global Genitourinary Drugs Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on indication, the market is divided into ovarian cancer, prostate cancer, bladder cancer, cervical cancer, erectile dysfunction, sexually transmitted diseases, interstitial cystitis, and benign prostatic hyperplasia, among others. The market on the basis of product is segmented into urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others. The regional markets for genitourinary drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global genitourinary drugs market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
- Bristol-Myers Squibb Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Pfizer Inc.
- Others
Market Share by Indication
Prostate cancer is anticipated to account for a leading share of the market for genitourinary drugs. This can be attributed to its wide prevalence, and the vast spectrum of treatments used to treat prostate cancer, including immunotherapy drugs, radiopharmaceuticals, and anti-neoplastic medicines.
The major causes of prostate cancer include an ageing population, obesity, diet, and family history. The genitourinary drugs market supports improved survival rates, slowed disease progression, and minimal side effects. Furthermore, it is projected that invasive operations won't be necessary in the future due to the developments in formulation techniques and next-generation therapies.
Market Share by Region
The genitourinary drugs market growth is predicted to be dominated by North America because of the region's expanding health care infrastructure, rising awareness of genitourinary problems, and rising need for better therapies and treatments for genitourinary diseases. During the course of the forecast period, the market expansion is anticipated to be fuelled by the rising prevalence of erectile dysfunction or ED in the United States.
During the projected period, the Asia Pacific market for genitourinary drugs is anticipated to expand at a profitable rate, fuelled by rising awareness in economies like China and India. The significant investments in research and development by major players and persistent efforts to market branded treatments at affordable prices are the driving forces for the market in the region. Rising disposable income will further increases the likelihood of using branded drugs, and ongoing improvements in healthcare infrastructure are also expected to support the market growth in the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Bristol-Myers Squibb Company, a multinational biopharmaceutical firm with headquarters in New York in the United States researches, develops, and distributes cutting-edge medications that aid patients in overcoming life-threatening illnesses. As part of its dedication to patient care, Bristol Myers Squibb works tirelessly to improve the quality of life for cancer patients as well as to define the future of cancer treatment. The business is renowned for its work in biological and pharmaceutical research.
Novartis AG, a Swiss corporation, is among the biggest producers of medications worldwide. Two significant Swiss pharmaceutical firms, Ciba-Geigy AG and Sandoz AG, combined to form Novartis in 1997. It offers medications for the treatment of infections, immunological disorders, ophthalmic and respiratory illnesses, cancer, cardiovascular diseases, dermatological issues, neurological disorders, and cancer.
F. Hoffmann-La Roche Ltd, a biotechnology business, with headquarters in Switzerland, creates medications and diagnostics to treat serious illnesses. It offers medications to treat conditions like cancer, autoimmune diseases, issues with central nervous systems, eye and vision problems, infectious diseases, and respiratory illnesses. Roche conducts research to find fresh approaches to preventing, diagnosing, and treating illnesses.
Other market players include Genentech, Inc. and Pfizer Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Genitourinary Drugs Market Overview
3.1 Global Genitourinary Drugs Market Historical Value (2017-2023)
3.2 Global Genitourinary Drugs Market Forecast Value (2024-2032)
4 Global Genitourinary Drugs Market Landscape
4.1 Global Genitourinary Drugs Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Genitourinary Drugs Product Landscape
4.2.1 Analysis by Indications
4.2.2 Analysis by Drug Type
4.2.3 Analysis by Distribution Channel
5 Global Genitourinary Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Genitourinary Drugs Market Segmentation
6.1 Global Genitourinary Drugs Market by Indications
6.1.1 Market Overview
6.1.2 Prostate Cancer
6.1.3 Ovarian Cancer
6.1.4 Bladder Cancer
6.1.5 Cervical Cancer
6.1.6 Renal Cancer
6.1.7 Erectile Dysfunction
6.1.8 Urinary Tract Infections
6.1.9 Overactive Bladder
6.1.10 Sexually Transmitted Diseases
6.1.11 Interstitial Cystitis
6.1.12 Hematuria
6.1.13 Benign Prostatic Hyperplasia
6.1.14 Others
6.2 Global Genitourinary Drugs Market by Drug Type
6.2.1 Market Overview
6.2.2 Hormonal Therapy
6.2.3 Impotence Agents
6.2.4 Uterine Relaxants
6.2.5 Urinary Antispasmodics
6.2.6 Urinary pH Modifiers
6.2.7 Uterine Stimulants
6.2.8 Miscellaneous Genitourinary
6.2.9 Tract Agents
6.2.10 Others
6.3 Global Genitourinary Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parentals
6.4 Global Genitourinary Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Online Pharmacy
6.4.4 Retail Pharmacy
6.5 Global Genitourinary Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Genitourinary Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Genitourinary Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Genitourinary Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Genitourinary Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Genitourinary Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Pfizer Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Astellas Pharma.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Allergan
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 GlaxoSmithKline plc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Antares Pharma
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Eli Lilly and Company
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Bayer AG, Merck KGaA
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Abbott
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Bristol-Myers Squibb Company
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Genentech
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 F. Hoffman-La Roche Ltd.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Novartis AG
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Teva Pharmaceutical Industries Ltd.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 AstraZeneca
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Advanz Pharmaceutical
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
19 Global Genitourinary Drugs Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market of genitourinary drugs attained a value of USD 48.46 billion.
The market is anticipated to grow at a CAGR of 3.1% during the forecast period of 2024-2032 to reach a value of USD 63.78 billion by 2032.
The major drivers of the genitourinary drugs market include rising frequency of genitourinary illnesses, improvements in the healthcare infrastructure, and increasing awareness about genitourinary disorders.
Increasing funding for research and development, rise in the number of pipeline drugs in late-stage clinical trials, and launch of next-generation therapeutics are the key industry trends propelling the growth of the market.
The major players in the industry are Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Genentech, Inc., and Pfizer Inc., among others.
Genitourinary drugs are used to treat infections to the genitourinary tract, congenital abnormalities, trauma, cancer, inflammation, iatrogenic injuries, and other ailments that cause damage to genitourinary organs.
The various genitourinary drug products are urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others.
All organs involved in reproduction as well as those involved in urine production and excretion make up the genitourinary system, for example, fallopian tubes, kidneys, prostate, and bladder.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER